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Abstract A sequence highly homologous to L1,4-N-acetylga-
lactosaminyltransferase III (L4GalNAc-T3) was found in a da-
tabase of human expressed sequence tags. The full-length open
reading frame of the gene, L4GalNAc-T4 (GenBank accession
number AB089939), was cloned using the 5P rapid ampli¢cation
of cDNA ends method. It encodes a typical type II transmem-
brane protein of 1039 amino acids having 42.6% identity with
L4GalNAc-T3. The recombinant enzyme transferred N-acetyl-
galactosamine to N-acetylglucosamine-L-benzyl with a L1,4-
linkage to form N,NP-diacetyllactosediamine as did L4Gal-
NAc-T3. In speci¢city toward oligosaccharide acceptor sub-
strates, it was quite similar to L4GalNAc-T3 in vitro, however,
the tissue distributions of the two enzymes were quite di¡erent.
These results indicated that the two enzymes have similar roles
in di¡erent tissues.
2 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
N-Glycan is a general term for a sugar chain covalently
bound to Asn on proteins. N,NP-Diacetyllactosediamine (Gal-
NAcL1-4GlcNAc, LacdiNAc) is an unusual constituent of N-
glycans in mammals. It has been found on glycoproteins and
glycohormones produced in certain tissues. Lutropin (LH),
thyrotropin [1], glycodelin [2] and tissue factor pathway inhib-
itor [3] are all glycoproteins carrying the LacdiNAc structure.
LH is a pituitary glycoprotein hormone which is essential for
the regulation of follicular maturation, ovulation and the se-
cretion of estradiol and progesterone. Both LH and follicle
stimulating hormone, consisting of a common K-subunit and
speci¢c L-subunit [4], are produced in the same cells, gonado-
trophs of the anterior pituitary, however, they di¡er in the
terminal structure of their N-glycans. The SO4-4GalNAcL1-
4GlcNAcL1-2Man structure on LH [5,6] is recognized by a
receptor in hepatic endothelial and Kup¡er cells to be cleared
rapidly from blood [7].
Glycodelin (Gd) is expressed in various cells of reproductive
organs and erythroid precursor cells of bone marrow [8^12].
The Gd isoform in amniotic £uid is called GdA, and the
corresponding isoform in seminal plasma GdS [13]. GdA car-
ries LacdiNAc, sialylated LacdiNAc (NeuAcK2-6GalNAcL1-
4GlcNAc) and a LacdiNAc analog of Lewis X (Lex, Gal-
NAcL1-4(FucK1-3)GlcNAc) at the non-reducing terminus, in
addition to LacNAc (GalL1-4GlcNAc), sialylated LacNAc
and Lex (NeuAcK2-6GalL1-4(FucK1-3)GlcNAc) [2], whereas
the major non-reducing epitopes on GdS are Lex and Ley
(FucK1-2GalL1-4(FucK1-3)GlcNAc) [14]. These isoforms of
Gd exhibit di¡erent biological functions directed by the car-
bohydrate epitopes. GdA, immunologically indistinguishable
from GdS, was reported to inhibit sperm^zona pellucida bind-
ing in a hemizona assay [15]. This may re£ect an important
role for GdA in fetomaternal defense [16]. In contrast, GdS
does not have this function [15]. Recently, Dell et al. reported
that zona pellucida 3 derived from mouse eggs expresses
O-glycans containing LacdiNAc [17].
Very recently, we cloned and characterized a L1,4-N-acetyl-
galactosaminyltransferase, L4GalNAc-T3, which synthesizes
the LacdiNAc structure in both N- and O-glycans [18]. L4Gal-
0014-5793 / 04 / $30.00 F 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/S0014-5793(04)00219-4
*Corresponding author. Fax: (81)-29-861 3201.
E-mail address: h.narimatsu@aist.go.jp (H. Narimatsu).
1 The nucleotide sequence reported in this paper has been registered
in the GenBank1/EBI Data Bank with accession numbers AB089939
and AB114827.
Abbreviations: LacdiNAc, N,NP-diacetyllactosediamine (GalNAcL1-
4GlcNAc); GalNAc, N-acetylgalactosamine; GlcNAc, N-acetylglu-
cosamine; LH, lutropin; Man, mannose; Gd, glycodelin; NeuAc,
N-acetylneuraminic acid; Gal, galactose; Le, Lewis; Lex, GalL1-
4(FucK1-3)GlcNAc; Fuc, fucose; Ley, FucK1-2GalL1-4(FucK1-
3)GlcNAc; L4GalNAc-T, L1,4-N-acetylgalactosaminyltransferase;
L4GT, L1,4-glycosyltransferase; EST, expressed sequence tag; ORF,
open reading frame; RACE, rapid ampli¢cation of cDNA ends;
HEK, human embryonic kidney; GlcA, glucuronic acid; pNp, para-
nitrophenyl; Bz, benzyl; Glc, glucose; Xyl, xylose; MS, mass spec-
trometry; MALDI-TOF, matrix-assisted laser desorption/ionization-
time of £ight; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
HPLC, high performance liquid chromatography
FEBS 28189 15-3-04
FEBS 28189FEBS Letters 562 (2004) 134^140
NAc-T3 was expressed in stomach, colon and testis at high
levels, but in brain at a very low level. Woodworth et al.
reported that tenascin-R associated with Purkinje cell bodies
and their dendrites in the molecular layer of the cerebellum
bears N-glycans terminating with SO4-4GalNAcL1-4GlcNAc
[19]. A high level of L4GalNAc-T activity was observed in
other regions of the brain in addition to the pituitary gland
and cerebellum [20]. This suggested the existence of an un-
known L4GalNAc-T which is responsible for the synthesis of
LacdiNAc in brain.
In this paper, we report the cloning and characterization of
a novel L4GalNAc-T, named L4GalNAc-T4, that is the sec-
ond such enzyme synthesizing the LacdiNAc structure. Con-
sidering the similar substrate speci¢cities of L4GalNAc-T4
and T3 in transfected cells and their di¡erent tissue distribu-
tion, we discuss their roles in vivo.
2. Materials and methods
2.1. Isolation of human L4GalNAc-T4 cDNAs
We performed a BLAST search of the GenBank1 database using
L4GT motifs, such as L4GalNAc-T3 (GenBank1 accession number
AB089940), as query sequences and identi¢ed an expressed sequence
tag (EST) with accession number N48738, which contained a partial
open reading frame (ORF) but showed high homology to the C-ter-
minal region of L4GalNAc-T3. To obtain the complete ORF, the 5P
rapid ampli¢cation of cDNA ends (5P-RACE) method was employed
using a Marathon-Ready1 cDNA Ampli¢cation Kit (Clontech, Palo
Alto, CA, USA). Two reverse primers, 5P-GCTCCTGCAGCTCCA-
GCTCCA-3P for the ¢rst polymerase chain reaction (PCR) and 5P-
AAGCGACTCCCTCGCGCCGAGT-3P for the nested PCR, were
employed for the extension. The approximately 0.6 kb fragment am-
pli¢ed did not contain a transmembrane domain, therefore, another
EST search was performed using the amino acid sequence of the
ampli¢ed fragment as a query, and an EST with accession number
BF058197 was found. The two sequences, N48738 and BF058197,
were not contiguous, therefore, it was con¢rmed they exist on a single
mRNA by reverse transcription (RT) PCR with two primers, 5P-AT-
GCCGCGGCTCCCGGTGAAGAAG-3P and 5P-AAGCGACTCCC-
TCGCGCCGAGT-3P. The sequences of the DNA fragments obtained
by the 5P-RACE method and RT-PCR were determined using a DYE-
namic ET Terminator Cycle Sequencing Kit (Amersham Biosciences,
Amersham, UK). Finally, a cDNA sequence encoding the ORF was
obtained by PCR using the Marathon-Ready1 cDNA of human
brain (Clontech) as a template.
2.2. Construction and puri¢cation of L4GalNAc-T4 and T3 proteins
fused with FLAG peptide
The putative catalytic domain of L4GalNAc-T4 (amino acids 62^
1039) was expressed as a secreted protein fused with a FLAG peptide
in human embryonic kidney HEK293T cells. An approximately 2.9 kb
DNA fragment was ampli¢ed by PCR using the Marathon-Ready1
cDNA derived from human whole brain as a template, and two prim-
ers, 5P-CCCAAGCTTCGGGGGGTCCACGCTGCGCCAT-3P and
5P-GCTCTAGACTCAAGACGCCCCCGTGCGAGA-3P. The ampli-
¢ed fragment was digested with the restriction endonucleases HindIII
and XbaI, then inserted into the HindIII-XbaI site of pFLAG-CMV-1
(Sigma, St. Louis, MO, USA) to construct pCMV/L4GalNAc-T4. The
construction method of the L4GalNAc-T3 expression vector was de-
scribed in detail in our previous paper [18].
The mouse L4GalNAc-T4 (mL4GalNAc-T4) gene encoding a puta-
tive catalytic domain (amino acids 45^1034) was ampli¢ed with 5P-
CCCAAGCTTCGCCTGGGCTACGGGCGAGAT-3P and 5P-GCT-
CTAGACTCAGGATCGCTGTGCGCGGGCA-3P using the cDNA
derived from mouse stomach as a template. The ampli¢ed 3.0 kb
fragment was digested with the restriction endonucleases HindIII
and XbaI, then inserted into pFLAG-CMV-1.
The catalytic domains of L4GalNAc-T4 and T3 were expressed in
HEK293T cells. A 50 ml volume of culture medium was mixed with
anti-FLAG M1 antibody resin (Sigma) and incubated with rotation at
4‡C overnight. The resin was washed twice with 50 mM Tris-bu¡ered
saline (50 mM Tris^HCl, pH 7.4, 150 mM NaCl) containing 1 mM
CaCl2 and suspended in 100 Wl of the assay bu¡er [18].
2.3. Assay for glycosyltransferase activity
To determine the enzyme activity, UDP-GalNAc, UDP-Gal, UDP-
GlcNAc, UDP-glucuronic acid (GlcA), GDP-mannose (Man), and
GDP-fucose (Fuc) (Sigma) were utilized as donor substrates. For ac-
ceptor substrates, monosaccharide acceptors (Table 1, numbers 1^13)
were purchased from Calbiochem (La Jolla, CA, USA) and Sigma. N-
and O-glycan-related acceptor substrates were purchased from Seika-
gaku, Takara (Shiga, Japan) and Honen (Tokyo, Japan). For the
GalNAc-T assay the method described in our previous paper was
utilized [18].
2.4. Determination of products of L4GalNAc-T4 with mass
spectrometry (MS) and 1H nuclear magnetic resonance (NMR)
spectra
The MS and NMR analyses were described in detail in our previous
paper [18]. A matrix-assisted laser desorption/ionization-time of £ight
(MALDI-TOF) MS (Re£ex IV, Bruker Daltonics, Billerica, MA,
USA) was used for the analysis. A one-dimensional 1H NMR spec-
trum was recorded with a DMX750 (Bruker, Germany, 750.13 MHz
for 1H nucleus) spectrometer at 25‡C.
Table 1
Substrate speci¢city of L4GalNAc-Ts
Acceptor substrate Relative activity (%)
L4GalNAc-T4 L4GalNAc-T3
1. GlcNAcL-Bz 100a 100a
2. GlcNAcK-Bz nd nd
3. GalK-pNp nd nd
4. GalL-oNp nd nd
5. GalNAcK-Bz nd nd
6. GalNAcL-Bz nd nd
7. GlcK-pNp nd nd
8. GlcL-pNp nd nd
9. GlcAL-pNp nd nd
10. FucK-pNP nd nd
11. ManK-pNp nd nd
12. XylK-pNp nd nd
13. XylL-pNp nd nd
14. GlcNAcL1-6(GalL1-3)GalNAcK-pNp (core 2-pNp) 15.2 11.4
15. GlcNAcL1-3GalNAcK-pNp (core 3-pNp) 20.0 32.3
16. GlcNAcL1-6GalNAcK-pNp (core 6-pNp) 190.7 220.4
aThe absolute activity of L4GalNAc-T4 and T3 was 2.43 and 8.28 nmol/ml medium/h, respectively.
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2.5. Quantitative analysis of L4GalNAc-T4 and T3 transcripts in
human tissues by real-time PCR
For the quanti¢cation of L4GalNAc-T4 and T3 transcripts, we em-
ployed the real-time PCR method, as described in detail previously
[21,22]. The primer set and the probe for the L4GalNAc-T4 gene were
as follows: the forward primer was 5P-GCTGCAGGCGGGAGTG-
3P, the reverse primer 5P-TGCCGTCCAGGATGTTGG-3P and the
probe 5P-GCGGTAGAGGACGCC-3P with a minor groove binder
[23]. The primer set and the probe for the L4GalNAc-T3 gene were
shown in our previous paper [18]. The relative amount of transcript
was normalized to the amount of glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) transcript in the same cDNA.
3. Results
3.1. Determination of nucleotide and putative amino acid
sequence of L4GalNAc-T4
We determined a novel full-length cDNA sequence by the
5P-RACE method and registered it in the GenBank1 database
with the accession number AB089939. The nucleotide se-
quence and putative amino acid sequence are shown in Fig.
1. The gene is located at 11p15 in the human genome data-
base, however, information on the genomic structure is insuf-
Fig. 1. Nucleotide and amino acid sequences of L4GalNAc-T4. The putative transmembrane domain is underlined. The DXH motif is written
in bold. The L1,4-glycosyltransferase (L4GT) motif is boxed. Possible N-glycosylation sites are indicated by open circles.
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¢cient for an analysis of the exon/intron structure. This ORF
consisted of 3120 bp encoding a predicted 1039 amino acid
protein with a typical type II topology, which is common in
glycosyltransferases. It contained three potential N-glycosyla-
tion sites and a DXH sequence, which is conserved in UDP-
GalNAc:polypeptide-GalNAc-Ts, and is thought to partici-
pate in divalent cation binding. In amino acid sequence,
L4GalNAc-T4 showed 42.6% identity with L4GalNAc-T3,
with highly conserved sequences in the N- and C-terminal
regions (Fig. 2). The middle region contained many acidic
amino acids and proline-rich stretches, and showed a rela-
tively low homology between the two enzymes. This region,
however, showed no homology with any identi¢ed proteins
except for L4GalNAc-T3. The L4GT motif, WGGED, is pres-
ent in the C-terminal region. A homologous gene was found
in the mouse (GenBank1 accession number AB114827) (data
not shown). It has 83.7% identity with human L4GalNAc-T4.
The mouse gene is probably orthologous to the human L4Gal-
NAc-T4 gene, and encoded a hypothetical 1042 amino acid
protein carrying three possible N-glycosylation sites, a DXH
sequence and a L4GT motif.
3.2. Substrate speci¢city of L4GalNAc-T4
We determined the substrate speci¢city of the truncated and
soluble L4GalNAc-T4 expressed in HEK293T cells. Utilizing
a variety of UDP donors and monosaccharide acceptors with
a para-nitrophenyl (pNp) or benzyl (Bz) group, donor and
acceptor substrates for L4GalNAc-T4 were screened with
high performance liquid chromatography (HPLC). As sum-
marized in Table 1, L4GalNAc-T4 transferred GalNAc to
the non-reducing end of GlcNAcL as did L4GalNAc-T3.
The relative levels of activity toward various acceptors were
Fig. 2. Multiple alignment of amino acid sequences of L4GalNAc-T4 and T3 performed with GENETYX. Introduced gaps are shown with hy-
phens. The putative transmembrane domains are underlined. The DXH motifs are written in bold. The L4GT motif, WGGED, is boxed. Iden-
tical amino acids are shown with asterisks. Possible N-glycosylation sites are indicated by arrowheads.
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similar between the two enzymes. A peak appeared at 24.8
min, in addition to the acceptor substrate peak at 30.3 min
(data not shown) when UDP-GalNAc and GlcNAcL-Bz were
used as a donor and an acceptor substrate, respectively. To
con¢rm that the additional peak was the real reaction product
of L4GalNAc-T4, it was isolated by reversed-phase HPLC
and identi¢ed with MALDI-TOF MS. In the positive-ion
mode, peaks of 515.221, 537.193 and 553.165 m/z appeared.
They were the same molecular mass as GalNAc-GlcNAc-Bz,
and GalNAc-GlcNAc-Bz with Naþ and with Kþ, respectively
(data not shown). However, no activity was observed with any
other donor and monosaccharide acceptor combination (Ta-
ble 1, numbers 1^13).
To determine the glycosidic linkage of the reaction product
of L4GalNAc-T4, 1H NMR spectroscopy was employed. In
the previous study, we determined the structure of the L4Gal-
NAc-T3 product as GalNAcL1-4GlcNAc-O-Bz by means of
NMR spectroscopy [18]. In the present study, the chemical
shifts from the L4GalNAc-T4 product, GalNAc-GlcNAc-O-
Bz, were compared to those of GalNAcL1-4GlcNAc-O-Bz
produced by L4GalNAc-T3. The NMR signals obtained
from the L4GalNAc-T4 product were almost identical to
those from GalNAcL1-4GlcNAc-O-Bz. Thus, we concluded
that the product of L4GalNAc-T4 has a L1-4 linkage like
the L4GalNAc-T3 product (data not shown).
3.3. Comparison of acceptor substrates
In the previous paper, we determined the speci¢city of
L4GalNAc-T3 for O- and N-glycans [18]. In the present study,
we compared the speci¢cities of two L4GalNAc-Ts toward O-
and N-glycan acceptors. In brief, the enzymes showed very
similar speci¢cities for O- and N-glycans, although the activity
of L4GalNAc-T3 was 3.4-fold higher than that of T4 (Table 1,
numbers 14^16, and Table 2). Among the O-glycan acceptor
substrates examined, the most e¡ective was core 6-pNp,
although it is a rare structure in O-glycans. The activity of
L4GalNAc-T4 toward core 6-pNp was 1.9-fold higher than
that toward GlcNAcL-Bz. Core 2-pNp (GalL1-3(GlcNAcL1-
6)GalNAcK1-pNp) and core 3-pNp (GlcNAcL1-3GalNAcK1-
pNp) could be acceptors, even with a relatively low e⁄ciency,
for L4GalNAc-T4 as for T3. Among the N-glycans examined,
the most e⁄cient substrate for both enzymes was a non-fuco-
sylated bi-antennary form (number 1 in Table 2). The e⁄-
ciency decreased as the number of antennas increased (data
not shown). The presence of an K1,6 Fuc residue had little
e¡ect in decreasing the activity of the enzymes (compare re-
sults between numbers 1 and 2, numbers 3 and 4, and num-
bers 5 and 6). L4GalNAc-T4 preferred the GlcNAcL1-
2ManK1-3 antenna to the GlcNAcL1-2ManK1-6 antenna as
an acceptor substrate as did L4GalNAc-T3 (numbers 3 and 5,
and 4 and 6).
Table 2
Substrate speci¢city of L4GalNAc-Ts
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3.4. Quantitative analysis of the L4GalNAc-T4 and T3
transcripts in human tissues and cell lines by real-time
PCR
In the present study, we determined the tissue distribution
and expression levels of the L4GalNAc-T4 transcript by the
real-time PCR method, and compared them with those of the
L4GalNAc-T3 transcript reported in our previous study. The
results are shown as the relative amount versus the GAPDH
transcript in Fig. 3. Interestingly, L4GalNAc-T3 transcript
was found to be very faint, while T4 was signi¢cantly ex-
pressed in adult and fetal brain (Fig. 3A). L4GalNAc-T4
was most highly expressed in ovary followed by fetal brain
and various adult brain tissues. It was also highly expressed in
fetal kidney and lung. L4GalNAc-T3 was expressed at an ex-
tremely low level in these tissues, while it was highly expressed
in adult stomach, colon and testis. The expression levels of
both enzymes in a variety of cell lines were comparatively low
(Fig. 3B), although some cell lines, PC-7 (lung adenocarcino-
ma) and GOTO (neuroblastoma) cells, showed a relatively
high level of L4GalNAc-T4.
4. Discussion
We found a novel L4GalNAc-T, named L4GalNAc-T4, car-
rying a L4GT motif, WGGED, in its C-terminus. Its amino
acid sequence was homologous to L4GalNAc-T3 with 42.6%
identity. The truncated protein produced in HEK293T cells
showed L4GalNAc-T activity toward GlcNAc, resulting in the
synthesis of LacdiNAc, as expected. Its ortholog was also
found in mouse. The speci¢city of L4GalNAc-T4 toward oli-
gosaccharides was quite similar to that of L4GalNAc-T3,
however, the tissue distribution of the two was di¡erent.
This is the second report of the molecular cloning and char-
acterization of a mammalian LacdiNAc synthase.
Fig. 3. Quantitative real-time PCR analysis of the L4GalNAc-T4 and T3 transcripts in human tissues and cell lines. Standard curves for L4Gal-
NAc-T4, T3 and GAPDH were generated by serial dilution of each plasmid DNA. The expression levels of the L4GalNAc-T4 (open bars) and
T3 (closed bars) transcripts were normalized to the level of GAPDH transcript, which was measured in the same cDNAs from human tissues
(A) and cell lines (B). Data were obtained from triplicate experiments and are indicated as the meanSS.D. PBMC, peripheral blood mononu-
clear cells; GOTO and SCCH-26, neuroblastomas; T98G and U251, glioblastomas; PC-7, lung adenocarcinoma; PC-1 and EBC-1, lung squa-
mous cells ; A431, esophagus cancer; MKN45, KATO III and HSC43, stomach cancers; Colo205, HCT15, LSC, LSB, SW480 and SW1116, co-
lorectal cancer; HepG2, hepatocarcinoma; Capan-2, pancreas cancer; SW1736, thyroid cancer; HL-60, promyelocytic leukemia; Namalwa, B
cell lymphoma; Daudi, B cell (Burkitt’s) lymphoma; K562, erythroid leukemia; HEK293, embryonic kidney cell ; HeLa and HeLa-S3, cervix
cancers.
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The L4GalNAc-T4 gene was found to be located at 11p15,
i.e. on a di¡erent chromosomal locus from the L4GalNAc-T3
gene at 12p13.3. The genomic information for L4GalNAc-T4
was insu⁄cient for the analysis of the exon/intron structure.
The L4GalNAc-T4 gene encodes a putative 1039 amino acid
protein which is unusually long in comparison with the other
glycosyltransferases. Comparing amino acid sequences be-
tween the two L4GalNAc-Ts, the N- and C-terminal regions
were found to be more homologous than the middle region
(Fig. 2). The middle of both L4GalNAc-T4 and T3 contains
an unusual sequence in which numerous Pro residues and
acidic amino acids, Glu and Asp, are present. The catalytic
activity of both L4GalNAc-Ts is probably directed by the
C-terminal region which contains the L4GT motif. Functions
of the N-terminal and middle regions remain to be elucidated.
This enzyme showed GalNAc-T activity toward GlcNAcL-
Bz as did L4GalNAc-T3 [18]. The product of L4GalNAc-T4,
GalNAc-GlcNAcL-Bz, showed the same spectrum as L4Gal-
NAc-T3 on one-dimensional 1H NMR spectroscopy as re-
ported previously by us [18]. Thus, the reaction product was
determined as GalNAcL1-4GlcNAc-O-Bz (data not shown).
Comparing the acceptor speci¢city between the two L4Gal-
NAc-Ts, their preference for oligosaccharides was remarkably
similar, that is, core 6-pNp and GlcNAcL-Bz were the pre-
ferred acceptors for both enzymes (Table 1). Furthermore, all
oligosaccharides containing non-reducing terminal GlcNAcL
residues could be acceptors for both L4GalNAc-Ts. Core 6
was preferable as an acceptor to core 2. The Gal residue of
core 2 might be obstructive to L4GalNAc-Ts. The similar
preference has been reported in L4Gal-Ts. Ujita et al. reported
that core 2 branch was not a suitable acceptor for L4Gal-T1
[24]. Thus, the activities of these L4GTs, i.e. L4Gal-Ts and
L4GalNAc-Ts, might be in£uenced by steric hindrance due
to the presence or absence of the Gal residue. Core 6 di¡ers
from core 3 only in the linkage between GlcNAc and Gal-
NAc. The former forms GlcNAcL1-6GalNAc whereas the
latter forms GlcNAcL1-3GalNAc. Both L4GalNAc-Ts can
recognize this di¡erence, and prefer core 6 to core 3. Core 6
is not a major core structure of O-glycan, in contrast to core 2
and 3 which are widely found as major core structures in
digestive organs, such as stomach and colon. However, the
core 6 structure and core 6 synthesizing activity have been
found in ovarian cyst £uid, seminal £uid and meconium
[26^28]. Core 6 in such tissues may be a physiological sub-
strate for L4GalNAcTs, because L4GalNAc-Ts were found to
be expressed in ovary and testis in the present study. In the
case of mouse, core 2 carrying LacdiNAc has been found in
mouse eggs [17]. This structure might be synthesized by
L4GalNAc-T3 in ovary. Very recently, we cloned L3Gal-
NAc-T2, which transfers GalNAc to GlcNAc with a L1-3
linkage, and prefers core 2 to core 3 or core 6 as an acceptor
[25]. It is possible that L3GalNAc-T2 competes with L4Gal-
NAc-Ts for core 2 containing acceptors in ovary and some
tissues, because both enzymes are expressed in such tissues.
However, the GalNAcL1-3GlcNAc structure has not been
found in mammalian tissues.
For the oligosaccharide acceptors of N-glycans, the Gal-
NAc transfer e⁄ciency of L4GalNAc-T4 and T3 decreased
as the number of antennas of N-glycan increased (data not
shown). The GlcNAcL1-2ManK1-3 antenna was preferred to
the GlcNAcL1-2ManK1-6 antenna. Dell et al. recently found
the LacdiNAc structures on N-glycans, however, they did not
determine which antenna has the structures [2]. The di¡eren-
tial tissue distribution of L4GalNAc-T4 and T3 suggested that
T4 is responsible for the in vivo synthesis of LacdiNAc on
GdA and LH. In adult and fetal brain, L4GalNAc-T4 was
expressed at high levels, while T3 was not. L4GalNAc-T4 is
probably responsible for the synthesis of LacdiNAc in the
N-glycan of tenascin-R which is present in the central nervous
system, including the cerebellum [19]. L4GalNAc-T4 was also
expressed in some fetal tissues, such as kidney and lung, while
T3 was expressed in stomach, colon and testis. In such tissues,
the proteins carrying LacdiNAc have yet to be identi¢ed. It is
of interest to ¢nd the proteins carrying LacdiNAc in these
tissues, and to investigate their speci¢c functions.
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